Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07366931

The Effect of Daily Supplementation With Humiome® Post LB on Gastrointestinal Symptoms in Female Athletes

Female athletes are often overlooked in scientific research, including the understanding of their digestive system and its impact on overall health, training, and performance. The gastrointestinal (GI) system plays a critical role in supporting digestion, nutrient absorption, and acting as a protective barrier for the body. While there is some knowledge about the differences in GI structure and function between males and females at rest, there is a lack of understanding regarding how these differences manifest during exercise, especially among female athletes and at different phases of the menstrual cycle.

It has been observed that female athletes commonly report a higher prevalence of GI symptoms compared to males, with many experiencing an increase during menstruation. These symptoms, including bloating, abdominal discomfort, and irregular bowel movements, can significantly disrupt an athlete's training and performance. Elite female athletes have acknowledged that GI symptoms associated with the menstrual cycle have led to altered or disrupted training routines. While these symptoms are commonly recognized to affect a large portion of the female population, few interventions have been studied to assist in managing this discomfort. Some clinicians may direct their patients to take pain-relieving medications without any thoughts on the consequences of chronic use.

One potential strategy to reduce GI symptoms during endurance exercise is probiotic-postbiotic supplementation. Various probiotic supplements have been shown to effectively decrease diarrhoea, constipation stress, and intestinal permeability, as well as impact immunologic outcomes. Postbiotics differ from probiotics in that they are made from microorganisms that are not alive. They allow the modulation of the composition and function of the gut microbiota and enhance the intestinal barrier to prevent unwanted substances from entering the body proper. While these biotics can relieve lower GI symptoms in irritable bowel syndrome (IBS), there is less consensus regarding their efficacy in modulating exercise-associated GI symptoms. Previous research by Pugh et al., 2019 has demonstrated that four weeks of probiotic supplementation was able to reduce GI symptoms during a marathon race, however this work was predominantly conducted in males and did not take menstrual cycle in consideration. This is important given that symptoms are commonly higher in the early follicular phase when a female experiences their period. Therefore, the aim of this study is to assess the effects of postbiotic supplementation on GI symptomology in female athletes.

The aim of this present study is to investigate the influence of postbiotic supplementation on menstrual cycle symptoms and exercise-associated GI symptoms in female endurance athletes while exercising compared to symptoms while taking a placebo.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Healthy Adult Females Gastrointestinal Symptoms

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Liverpool John Moores University

Liverpool, United Kingdom

Location contact

Kat Silang

CONTACT

[email protected]

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female, cisgender, premenopausal.
  • Minimum age 18 years.
  • Regular, natural menstrual cycle (21-35 days in duration), with 9 or more consecutive periods per year, if possible documented with tracker apps, calendars, or other tools.
  • Willingness and ability to give informed consent and to understand, to participate, and to comply with the clinical study requirements.
  • Body mass index (BMI) ≥ 18.5 and < 24.9 kg/m2
  • Agreeing to maintain lifestyle habits during the study (same dietary and physical activity habits)
  • Having a smartphone and a history of consistent tracking of training and health records via apps.
  • Having regular GI issues during exercise, preferably also during menstruation. During pre-screening, this will be assessed with a shortened GSRS questionnaire, where participants need to have had, in the month preceding pre-screening, the equivalent of at least a score of 2 in a GSRS focus area (diarrhoea, pain, indigestion).
  • No relevant self-reported abnormalities from medical history.
  • Trained athlete (trains at least 3 times per week for more than 1 hour per day and who has been involved in endurance training for at least 2 years in alignment with previous research (Pfeiffer et al., 2010). This will be evaluated by assessing training records (Strava or similar application, certificates of attendance to athletic events, club membership, etc.).
  • Access to a health-care provider, who can be contacted by the CRO, and who reside in areas with available health services.

Exclusion criteria

  • Individuals who are pregnant, lactating, or plan to become pregnant before study end.
  • Individuals with secondary amenorrhea.
  • Individuals who use hormonal contraceptives during the last 6 months before (and during) the trial.
  • Individuals who are currently participating in another clinical trial or have participated in a trial within the last two months prior to enrolment.
  • Tobacco smokers and vapers.
  • Individuals with acute illness.
  • Individuals with a current musculoskeletal injury or one within the last month.
  • Individuals taking probiotic supplements or who have taken probiotics two weeks prior to enrolment.
  • Individuals controlling chronic diseases with treatments known to alter the intestinal microbiome or to alter GI symptoms, such as certain pain killers, antacids, proton-pump inhibitors, anti-diarrhoeal medication or supplements, and laxatives.
  • Individuals having received antibiotics treatments within three months of trial start.
  • Individuals having planned major changes in lifestyle (i.e. diet, weight loss program, exercise level, travelling) during the duration of the study.
  • Individuals who have any hypersensitivity/allergy to any of the components of the test product.
  • Individuals who have planned major elective surgery during the study period.

Treatment and study plan

Postbiotic

Drug

Participants allocated to this arm will receive the investigational product (Humiome(R) Post LB), to be ingested daily for three consecutive menstrual cycles.

Placebo

Drug

Participants allocated to this arm will receive a visually identical placebo to the verum, to be ingested daily for three consecutive menstrual cycles.

Primary outcomes

  1. Gastrointestinal Symptom Rating Scale (GSRS) scores

    Time frame: Starting from Day 1 of the participants' menstrual cycle, the questionnaire is to be completed every seven days for the duration of the trial, an average of three months.

    A list of fifteen gastrointestinal symptoms scored on a Likert scale, where 1=no discomfort at all, and 7=very severe discomfort.

Secondary outcomes

  1. Gastrointestinal Symptom Rating Scale (GSRS) Sub-scores

    Time frame: Starting from Day 1 of the participants' menstrual cycle, the questionnaire is to be completed every seven days for the duration of the trial, an average of three months.

    A list of fifteen gastrointestinal symptoms scored on a Likert scale, where 1=no discomfort at all, and 7=very severe discomfort. The symptoms are grouped into five sub-categories: Reflux, Abdominal pain, Indigestion, Diarrhoea, and Constipation.

  2. Wilson Gastrointestinal (GI) Score

    Time frame: Questionnaire to be completed once a day on the days the participants are menstruating. An average of 5 days every cycle, for the duration of the trial, an average of three months.

    A list of six gastrointestinal symptoms scored on a Likert scale, with the following descriptors:

    0=no discomfort 5=moderate discomfort 10=unbearable discomfort.

  3. Faecal microbiome composition

    Time frame: Two times throughout participation (average of three months); first sample is taken after the first month of participation, and second sample taken after the third month of participation. Exact times vary from participant to participant.

    Faecal samples will be collected to assess gut microbial composition using full shotgun sequencing.

  4. Faecal microbiome diversity

    Time frame: Two times throughout participation (average of three months); first sample is taken after the first month of participation, and second sample taken after the third month of participation. Exact times vary from participant to participant.

    Faecal samples will be collected to assess gut microbial diversity using full shotgun sequencing.

  5. Adherence to physical activity training schedules

    Time frame: Starting from Day 1 of the participants' menstrual cycle, the diary is to be completed every seven days for the duration of the trial, an average of three months.

    Participants will be asked to complete a weekly training diary where they will provide any planned training activities and their adherence to these plans. Data taken will be minutes of activity per week and intensity of the training.

Sponsors and collaborators

Lead sponsor

Liverpool John Moores University

Other

Collaborators

  • dsm-firmenich Switzerland AG

Registry information

Official study title

A Randomized, Placebo-controlled, Double-blind Trial on the Effect of Daily Supplementation With Humiome® Post LB on Gastrointestinal Symptoms in Female Athletes

Acronym: GI-Jane

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jan 26, 2026
Registry last updated
Jan 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.